Bupropion extended-release for depressive disorders

Expert Review of Neurotherapeutics

Volumn 8, Issue 5, 2008, Pages 715-722

  Jefferson, James W ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Madison Institute of Medicine   (United States)

Author keywords

Clinical trial; Depression; Extended release bupropion; Mechanism of action

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B6; DOPAMINE; ELONTRIL; ESCITALOPRAM; MAGERION; MONOAMINE; NORADRENALIN; PLACEBO; RADAFAXINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; VOXRA; WELLBUTRIN RETARD; WELLBUTRIN XR;

ANXIETY; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; HAMILTON SCALE; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROPHARMACOLOGY; NONHUMAN; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; STEREOCHEMISTRY; WEIGHT GAIN; XEROSTOMIA;

AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; HUMANS; TREATMENT OUTCOME;

EID: 43249089600     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.5.715     Document Type: Review

References (54)

1. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 617-627 (2005).
2. Kessler RC, Berglund P, Demler O, Jin R, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62, 593-602 (2005).
3. Conway KP, Comptom W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 67, 247-257 (2006).
4. Alonso J, Lépine J-P. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMed). J. Clin. Psychiatry 68(Suppl. 2), 3-9 (2007).
5. Laursen TM, Munk-Olsen T, Nordetoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry 68, 899-907 (2007).
6. Ösby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry 58, 844-850 (2001).
7. Stahl SM. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int. J. Neuropsychopharmacol. 10, 575-578 (2007).
8. Mehta NB. The chemistry of bupropion. J. Clin. Psychiatry 44(Sec. 2), 56-59 (1983).
9. Mehta DK, Aronson JK. Give a drug a good name. Lancet 369, 1326-1328 (2007).
10. Ferris RM, Cooper BR, Maxwell RA. Studies of bupropion's mechanism of antidepressant activity. J. Clin. Psychiatry 44(Sec. 2), 74-78 (1983).
11. Fabre LF, McLendon D, Mallette A. A double blind trial of bupropion hydrochloride - a novel antidepressant. Clin. Pharmacol. Ther. 21, 102 (1977).
12. Horne RL, Ferguson JM, Pope HG et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J. Clin. Psychiatry 49, 262-266 (1988).
13. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert. Rev. Neurotherapeutics 6(9), 1249-1265 (2006). •• Excellent review of bupropion.
14. Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J. Pharmacol. Exp. Ther. 289(2), 877-885 (1999).
15. Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J. Clin. Psychiatry 64(Suppl. 13), 5-12 (2003).
16. Damaj MI, Carroll FI, Eaton JB et al. Enantioselective effects of hydroxyl metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol. Pharmacol. 66, 675-682 (2004).
17. Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacolgy 163, 102-105 (2002).
18. Learned-Coughlin SM, Bergström M, Savitcheva I, Ascher J, Schmith VD. The in vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol. Psychiatry 54, 800-805 (2003).
19. El Mansari M, Ghanbari R, Janssen S, Blier P. Effects of long-term treatment with bupropion on the firing activity of serotonin and norepinephrine neurons. Eur. Neuropsychopharmacol. 17(Suppl. 4), S173-S638 (2007).
20. Rau KS, Birdsall E, Hanson JE et al. Bupropion increases striatal vesicular monoamine transport. Neuropharmacology 49, 820-830 (2005).
21. Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin. Ther. 27, 1685-1695 (2005). • Good review of pharmacokinetics and formulations of bupropion.
22. Kirchheiner J, Klein C, Meineke I et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13(10), 619-626 (2003).
23. Clayton AH. Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? Expert. Opin. Pharmacother. 8(4), 457-466 (2007). •• Thorough clinical review of extended-release bupropion.
24. Thase ME, Haight BR, Richard N et al. Emission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J. Clin. Psychiatry 66, 974-981 (2005).
25. Clayton AH, Croft HA, Horrigan JP et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J. Clin. Psychiatry 67, 736-746 (2006). • Low incidence of sexual dysfunction with bupropion.
26. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR. J. Clin. Psychopharmacol. 26, 482-488 (2006).
27. Chrzanowski W, Rousseau R, Hewett K et al. Efficacy and safety of bupropion extended release in elderly patients with major depressive disorder. Eur. Neuropsychopharmacol. 16(Suppl. 4), S315 (2006).
28. Jefferson JW, Rush AJ, Nelson JC et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 67, 865-873 (2006). • Clinical trial in a common subtype of depression.
29. Papakostas GI, Nutt DJ, Hallett LA, Rucker VL, Krishen A, Fava M. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol. Psychiatry 60, 1350-1355 (2006).
30. Wellbutrin XL® Prescribing Information. GlaxoSmithKline, Research Triangle Park, NC (2007).
31. Modell, JG, Rosenthal NE, Harriett AE et al. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol. Psychiatry 58, 658-667 (2005). • Pivotal clinical trial.
32. Zimmerman M, Posternak M, Friedman M et al. Which factors influence psychiatrists' selection of antidepressants? Am. J. Psychiatry 161(7), 1285-1289 (2004).
33. Weihs KL, Houser TL, Batey SR et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol. Psychiatry 51(9), 753-671 (2002).
34. Zimmerman M, Posternak MA, Attiullah N et al. Why isn't bupropion the most frequently prescribed antidepressant? J. Clin. Psychiatry 55, 603-610 (2005).
35. Thase ME, Haight BR, Modell JG, Rockett CB, Asgharian A. Lack of effect of bupropion sustained release on blood pressure in hypertensive patients. Proceedings of 156th American Psychiatric Association Meeting. San Francisco, May 17-22, CA, USA, NR841 (2003).
36. Kotlyar M, Brauer LH, Tracy TS et al. Inhibition of CYP2D6 activity by bupropion. J. Clin. Psychopharmacol 25, 226-229 (2005).
37. Hays JT, Ebbert JO. Bupropion for the treatment of tobacco dependence. CNS Drugs 17(2), 71-83 (2003).
38. Wilens TE, Haight BR, Horrigan JP et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol. Psychiatry 57, 793-801 (2005).
39. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes. Res. 10(7), 633-641 (2002).
40. Sachs GS, Lafer B, Stoll AL et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J. Clin. Psychiatry 55(9), 391-393 (1994).
41. Sachs GS, Nierenberg AA, Calabrese JR et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Engl. J. Med. 356, 1711-1722 (2007).
42. Post RM, Altshuler LL, Leverich GS et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br. J. Psychiatry 189, 124-131 (2006).
43. Semenchuk MR, Sherman S, David B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 57, 1583-1588 (2001).
44. Bystritsky A, Kerwin L, Vapnik T. A pilot controlled trial of bupropion versus escitalopram in GAD. Proceedings of the 159th American Psychiatric Association Meeting. May 20, Toronto, Canada, NR638 (2006).
45. DeBattista C, Solvason B, Poirier J, Kendrick E, Loraas E. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J. Clin. Psychiatry 66, 844-848 (2005).
46. Masand PS, Ashton AK, Gupta S, Frank B. Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study. Am. J. Psychiatry 158(5), 805-807 (2001).
47. Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J. Clin. Psychiatry 65, 62-67 (2004).
48. Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MBP. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-α and interferon-γ in mice. Int. Immunopharmacol. 6, 903-907 (2006).
49. Stang P, Young S, Hogue S. Better patient persistence with once-daily bupropion compared with twice-daily bupropion. Am. J. Ther. 14, 20-24 (2007).
50. Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur. Neuropsychopharmacol. 16, 391-402 (2006).
51. Nutt D, Demyttenaere K, Janka Z et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J. Psychopharmacol. 21, 461-471 (2007). • Timely focus on catecholamines and depression.
52. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 64, 327-337 (2007). • Explores dopaminergic dysfunction and depression.
53. WHO: Depression www.who.int/mental_health/management/depression/ definition/en/print.html
54. Geocities.com: Wellbutrin IR® http://geocities.com/adrforall2007/ WellIRNDAPg226.htm